The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes

NCT01281228 · Completed

Last updated 2026-05-28

This clinical trial tests how a GLP-1 receptor activator affects brain signals related to hunger and reward in adults with type 2 diabetes and obesity.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, single-blind study

Participants 48 people

Who can join Ages 18–70 · all sexes Healthy volunteers accepted.

Timeline Started 2011-09 · est. completion 2013-10

Where 1 site · Netherlands

What this study is testing ClinicalTrials.gov NCT01281228 ↗

Description as written by the study sponsor.

Glucagon-like peptide 1 (GLP-1) based therapies, such as exenatide, are already successfully employed in the treatment of Type 2 Diabetes (T2DM). Exenatide improves glycemic control and is associated with reduced food intake and body weight. The investigators hypothesize that it affects central reward and satiety circuits and that this may contribute to the weight loss.

Treatments tested

exenatide also known as Byetta Drug

The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests.
exenatide + exendin (9-39) Drug

The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests. Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min.
placebo Drug

saline infusion

Main thing measured	Differences in neuronal activity in CNS reward and satiety circuits
Sponsor	Amsterdam UMC, location VUmc
Conditions studied	Diabetes Mellitus, Diabetes Mellitus, Type 2, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01281228 ↗